Biophagy is awarded a New Mexico Small Business Assistance (NMSBA) leverage grant with Sandia National Laboratories to lead a team of four companies (including Avisa Pharma, PureInfo Discovery, and Omphalos Biosciences) to investigate binding dynamics of several proprietary autophagy stimulants on cytoskeleton and lysosome movement. They will also study compound enhancement of antibiotic killing using M. bovis, in mouse macrophages. This is a surrogate assay for tuberculosis.
Biophagy, working with Sandia National Laboratories, is awarded an individual company grant from NMSBA to study the relative potencies and binding sites of several autophagy stimulant combinations.
Biophagy, working with Sandia National Laboratories, is awarded an individual company grant from NMSBA to study the binding sites and autophagy stimulating activities of several UNM compounds under consideration for licensing.
Albuquerque Business First awards Dr. Mary Ortner, Biophagy’s CEO, its Woman of Influence award in recognition of her contributions to business development in Albuquerque.
